Synapse - Rohit Thummalapalli

Results (22)

Consolidation osimertinib versus durvalumab versus observation after concurrent chemoradiation in unresectable EGFR-mutant NSCLC: A multicenter retrospective cohort study

Journal Article

Nassar, A. H.; Kim, S. Y.; Aredo, J. V.; Feng, J.; Shepherd, F.; Xu, C.; Kaldas, D.; Gray, J. E.; Dilling, T. J.; Neal, J. W.; more...
Journal of Thoracic Oncology (2024)

Fulltext@MSK | Save

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

Journal Article

Middha, P.; Thummalapalli, R.; Betti, M. J.; Yao, L.; Quandt, Z.; Balaratnam, K.; Bejan, C. A.; Cardenas, E.; Falcon, C. J.; Faleck, D. M.; more...
Nature Communications (2024)

Fulltext@MSK | Save

Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma

Journal Article

Li, Z.; Zhuang, X.; Pan, C. H.; Yan, Y.; Thummalapalli, R.; Hallin, J.; Torborg, S.; Singhal, A.; Chang, J. C.; Manchado, E.; more...
Cancer Discovery (2024)

Fulltext@MSK | Save

Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer

Journal Article

Thummalapalli, R.; Bernstein, E.; Herzberg, B.; Li, B. T.; Iqbal, A.; Preeshagul, I.; Santini, F. C.; Eng, J.; Ladanyi, M.; Yang, S. R.; more...
JCO Precision Oncology (2023)

Fulltext@MSK | Save

Outcomes of combination platinum-doublet chemotherapy and anti-PD(L)-1 blockade in KRAS(G12C) mutant non-small cell lung cancer

Journal Article

Elkrief, A.; Riccuiti, B.; Alessi, J. V.; Fei, T.; Kalvin, H. L.; Egger, J. V.; Rizvi, H.; Thummalapalli, R.; Lamberti, G.; Plodkowski, A.; more...
The Oncologist (2023)

Fulltext@MSK | Save

Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer

Journal Article

Thummalapalli, R.; Ricciuti, B.; Bandlamudi, C.; Muldoon, D.; Rizvi, H.; Elkrief, A.; Luo, J.; Alessi, J. V.; Pecci, F.; Lamberti, G.; more...
Clinical Cancer Research (2023)

Fulltext@MSK | Save

Factors associated with disease progression after discontinuation of immunotherapy for immune-related toxicity in non-small cell lung cancer

Meeting Abstract

Pecci, F.; Thummalapalli, R.; Alden, S.; Ricciuti, B.; Alessi, J. V.; Elkrief, A.; Rizvi, H.; Wang, X.; Egger, J. V.; Vaz, V. R.; more...
Journal of Thoracic Oncology (2023)

Fulltext@MSK | Save

Consolidation EGFR-tyrosine kinase inhibitor (TKI)vs. durvalumab vs. observation in unresectable EGFR-mutant stage III NSCLC

Meeting Abstract

Nassar, A. H.; Adib, E.; Kaldas, D.; Feng, J.; AbuAli, T.; Aredo, J.; Fitzgerald, B.; Bar, J.; Thummalapalli, R.; Parikh, K.; more...
Journal of Thoracic Oncology (2023)

Fulltext@MSK | Save

Lorlatinib tolerability and association with clinical outcomes in patients with advanced ALK- or ROS1-rearranged NSCLC: A brief report

Journal Article

Thummalapalli, R.; Choudhury, N. J.; Ehrich, F.; Beardslee, T.; Brazel, D.; Zhang, S. S.; Merchant, S.; Chen, M. F.; Heller, G.; Ramalingam, S. S.; more...
JTO Clinical and Research Reports (2023)

Fulltext@MSK | Save

Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer

Meeting Abstract

Thummalapalli, R.; Ricciuti, B.; Bandlamudi, C.; Muldoon, D.; Luo, J.; Alessi, J. V. M.; Pecci, F.; Lamberti, G.; Hong, Lingzhi; Plodkowski, A. J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save